Loading briefing details...
Loading briefing details...
News Briefs
By: Brief The Press
Category: Health, Industry, Science & Environment
March 21, 2026
This upgrade to Creative Biolabs' rodent behavioral platform is crucial for CNS drug discovery. By providing more predictive preclinical models and reducing the translational gap, it promises to lower the high attrition rates for neurodegenerative disease therapies, ultimately accelerating the development of effective treatments for patients. This advancement offers robust, actionable data for regulatory success.
SHIRLEY, NY – March 21, 2026 – Creative Biolabs has significantly upgraded its comprehensive rodent behavioral profiling platform, specifically designed to accelerate central nervous system (CNS) drug discovery. This advanced platform offers highly standardized evaluations of both cognitive and motor functions, aiming to reduce the critical translational gap in developing therapeutics for neurodegenerative diseases like Alzheimer's (AD) and Parkinson's (PD). The initiative directly addresses the historically high clinical attrition rates for CNS therapeutics, often due to a lack of predictive preclinical models that accurately reflect complex human neuropathology.
The enhanced platform integrates sophisticated cognitive and neuromuscular assessments to provide a holistic efficacy profile for pipeline candidates. For cognitive function, industry-standard paradigms such as the Morris Water Maze (MWM), Novel Object Recognition (NOR), and Y-Maze quantitatively evaluate spatial learning, working memory, and recognition with high analytical precision. Simultaneously, advanced motor function assessments, including automated Rotarod tests, grip strength measurements, and open-field locomotor tracking, are critically configured to detect subtle therapeutic improvements or neurotoxicities in motor coordination, balance, and muscle endurance.
Creative Biolabs overcomes common preclinical translation challenges through stringent operational protocols, including minimizing environmental variability with automated video tracking and strict controls, and ensuring optimal model-to-assay alignment. “The predictive validity of any CNS animal model relies heavily on the sensitivity and reproducibility of the behavioral assays applied,” stated the Director of In Vivo Pharmacology at Creative Biolabs. “Integrating these dual-assessment platforms has successfully supported multiple IND applications for novel neuroprotective agents, empowering developers to generate robust, actionable data that withstands rigorous regulatory scrutiny.”